Join
Live feed
·
PRReleasevia Quantisnow
I-MAB logo

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

ByQuantisnow·Wall Street's wire, on your screen.
IMAB· I-MAB
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMAB (I-MAB) and more on Quantisnow.